Melero J A, Gonzalez-Rodriguez J
Eur J Biochem. 1984 Jun 1;141(2):421-7. doi: 10.1111/j.1432-1033.1984.tb08208.x.
Monoclonal antibodies against purified glycoprotein IIIa (GPIIIa) of human platelet membranes have been obtained. These antibodies, except one, are able to bind to intact platelets; the exception is M108/p98 antibody which recognizes a new epitope, unmasked after proteolysis of GPIIIa in vitro. Several antigenic areas can be delineated on the molecule, by testing the ability of different antibodies to compete in their simultaneous binding to GPIIIa. One of the monoclonal antibodies inhibits ADP-induced platelet aggregation while others do not have an effect or induce agglutination of platelets independent of ADP. Conventional antiserum raised against purified GPIIIa also blocks the aggregation induced by ADP. These results favour the hypothesis that GPIIIa plays a direct role in the mechanism of platelet aggregation.
已获得针对人血小板膜纯化糖蛋白IIIa(GPIIIa)的单克隆抗体。这些抗体,除一种外,均能与完整血小板结合;例外的是M108/p98抗体,它识别一个新表位,该表位在体外GPIIIa经蛋白酶解后暴露。通过测试不同抗体同时结合GPIIIa时的竞争能力,可在该分子上划定几个抗原区域。其中一种单克隆抗体可抑制ADP诱导的血小板聚集,而其他抗体则无作用或诱导血小板凝集,且与ADP无关。针对纯化GPIIIa产生的传统抗血清也能阻断ADP诱导的聚集。这些结果支持了GPIIIa在血小板聚集机制中起直接作用这一假说。